Understanding the Market | HAIXI PHARMA once rose over 12%, more than 30% higher than the offering price, with a dual-line layout of generic drugs and innovative drugs

HAIXI PHARMA once rose over 12%, reaching HKD 114.9, an increase of over 30% compared to the offering price of HKD 86.4. As of the time of writing, it has risen 9.2%, trading at HKD 111.6, with a transaction volume of HKD 20.9312 million. It is reported that HAIXI PHARMA is a pharmaceutical company in the commercialization stage, integrating research and development, production, and sales capabilities, with a pipeline of innovative drugs under research. As of the disclosure date of the prospectus, HAIXI PHARMA has 15 approved generic drug products, covering multiple therapeutic areas, including the digestive system, cardiovascular system, endocrine system, and nervous system. The company has also established a pipeline of four innovative drugs under research, covering cancer, ophthalmology, and respiratory diseases. HAIXI PHARMA previously stated in its prospectus that it plans to actively explore opportunities for collaboration with multinational companies (MNCs) in the future to expand the company's international clinical research and commercialization capabilities